Founder & CEO
Corey Bridges is the Chief Executive Officer and Co-Founder of LifeMap Solutions, Inc., a subsidiary of BioTime, Inc. Prior to the creation of LifeMap Solutions, Mr. Bridges served as Vice President of Marketing for James Cameron’s CAMERON | PACE Group (CPG), where he developed and implemented international expansion plans responsible for bringing the cinematic technology company to Europe and China. Before working with CPG, he was Chief Marketing Officer and Executive Producer for Multiverse, where he oversaw marketing, sales, and business development. Throughout his career, Mr. Bridges has focused on bringing positively disruptive companies to market. Additional professional highlights include launching Netflix and product-managing Internet pioneer Netscape’s flagship web browser. Mr. Bridges is a graduate of the University of California, Berkeley.
Chief Technology Officer & Head of Product
Rafhael Cedeno is the Chief Technology Officer and Head of Product for LifeMap Solutions, Inc., and leads the engineering team in the development of an advanced mHealth platform. Mr. Cedeno was instrumental in creating the first versions of ubiquitous internet technologies and services such as web crawlers, blogs, and widgets during his time at web pioneers like Netscape and Themestream. He is known for designing creative and interactive products while ensuring value and product-market fit. Before joining LifeMap Solutions, Mr. Cedeno was Director of Global Distribution at Groupon, a global leader of local commerce. Prior to that, he was Vice President of Game Development at Viacom, where he was responsible for overseeing the growth of several chart-topping mobile apps.
Robert W. Peabody
Chief Financial Officer
Robert W. Peabody is the Chief Financial Officer of LifeMap Solutions, Inc. Prior to that he was the Senior Vice-President and Chief Financial Officer at BioTime, Inc. Prior to joining BioTime in October 2007, Mr. Peabody served as Vice-President of Grant Administration for Advanced Cell Technology, Inc., and also served on their board of directors from 1998 to 2006. Prior to joining ACT, Mr. Peabody spent 14 years as a Regional Controller for Ecolab, Inc., a Fortune 500 specialty chemical manufacturer and service company. Mr. Peabody, along with Dr. West, was a co-founder of Geron Corporation of Menlo Park, CA. He has also been an audit manager for Ernst and Young where he was on the audit staff serving the firm’s clients whose shares are publicly traded. Mr. Peabody received a Bachelor Degree in Business Administration from the University of Michigan.
Ph.D., Senior Bioinformatics Software Developer
Steve Hershman is a Senior Scientist, Full Stack Engineer, Designer, and Business Analyst at LifeMap Solutions Inc. He has over a decade of experience tackling technical challenges related to medicine. Dr. Hershman was previously co-founder of Genterpret, a Blueprint Health accelerator company. He holds BA, MS and MSE degrees from the University of Pennsylvania and a PhD in Systems Biology and the Leder Human Biology & Translational Medicine Program from Harvard University.
Science Team from Mount Sinai School of Medicine
Ph.D., Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine
Eric Schadt is the Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine, and serves as lead science advisor to LifeMap Solutions, Inc. Prior to joining Mount Sinai in 2011, Dr. Schadt was Chief Scientific Officer at Pacific Biosciences, Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and a Senior Research Scientist at Roche Bioscience. He is known for his work in the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. Dr. Schadt received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles.
Yu-Feng Yvonne Chan
MD, PhD, FACEP, Director, Personalized Medicine and Digital Health
Dr. Yvonne Chan is a board-certified Emergency Medicine physician with a PhD in clinical research as well as experience in mobile health applications, personalized medicine, pharmacogenomics, genomics, clinical trials and patient education. Dr. Chan is the Director of Personalized Medicine (PM) and Digital Health (DH) at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. Her role is to lead the Institute in study design, execution, and management of all DH and PM related initiatives conducted at the Icahn Institute. She also serves as the collaborator and client liaison for these projects.
M.S., C.G.C., Head of Genomics and Integrative Health Innovations
Elissa Levin is the Head of Genomics and Integrative Health Innovations at Mount Sinai School of Medicine, and serves as a science advisor to LifeMap Solutions, Inc. Prior to Mount Sinai, Ms. Levin served as Director of Clinical Support Services at life technology company ThermoFisher Scientific, Vice President of Genomic Services at Navigenics, and Director of Clinical Services at DNA Direct. She received a B.A. in history and psychology from Tufts University, and her M.S. and C.G.C. in Genetic Counseling from Arcadia University.
Ph.D., Director of Clinical Genome Informatics
Rong Chen is the Director of Clinical Genome Informatics at Mount Sinai School of Medicine, and serves as a science advisor to LifeMap Solutions, Inc. Prior to Mount Sinai, Dr. Chen led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA’s contract for the Million Veteran Genome project. Dr. Chen received a B.S. in chemical physics from the University of Science and Technology of China, and a Ph.D. in bioinformatics from Boston University.
Board of Directors
Alfred D. Kingsley
Ph.D., Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine
Alfred D. Kingsley is also Chairman of the Board of BioTime, Inc. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Mr. Kingsley was Senior Vice President of Icahn and Company and its affiliated entities for more than 25 years.
Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.
Louis E. Silverman
Mr. Silverman joined LifeMap Sciences’ board of directors in October 2012. Mr. Silverman is an experienced healthcare executive with board level and operating experience in healthcare IT, pharmaceuticals, home health care, worker’s compensation managed care and revenue cycle management. Currently, Mr. Silverman is Chairman and CEO of Advanced ICU Care, the largest independent provider of telemedicine solutions to hospital intensive care units in the US. From September 2009 through to its successful sale in June of 2012, Mr. Silverman was the Chief Executive Officer of privately held Marina Medical Billing Service Inc., a company focused on providing revenue cycle management services nationally to emergency room physicians. Prior to joining Marina Medical, Mr. Silverman was President and Chief Executive Officer of Lifecomm, Inc., a Qualcomm Incorporated incubated wireless health services start-up. From 2000 – 2008, Mr. Silverman was President and Chief Executive Officer of Quality Systems, Inc., a developer of medical and dental practice management software, which he led to significant revenue growth and an increase in market value from $42 million to $1.2 billion. Previously, Mr. Silverman was the Chief Operations Officer of Corvel Corporation. Mr. Silverman currently serves as a member of the Board of Directors of STAAR Surgical (NASDAQ: STAA) and also serves as Chairman of the Board of Comarco, Inc.(OTC :CMRO.PK).
Mr. Silverman earned a Bachelor of Arts degree from Amherst College and a Masters in Business Administration from Harvard Graduate School of Business Administration.
Michael D. West, Ph.D., is the key driving force behind the concept of the LifeMap Discovery database. He is a pioneer in the field of stem cell research and has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development. Dr. West is the CEO of BioTime, Inc. and has served on the BioTime Board of Directors since 2002. Prior to joining BioTime, Dr. West served as President and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Dr. West also founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells, and he initiated and managed the original collaborative effort that led to the first isolation of human embryonic stem and embryonic germ cells. Dr. West is an inventor named on over 100 patents and patent applications in the field of gerontology and regenerative medicine.
Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. Dr. West’s complete CV and background on his research interests are available online at: www.michaelwest.org
Michael H. Mulroy joined LifeMap board of directors in November 2015. He is also a member of the BioTime Board of Directors. Mr. Mulroy is a business consultant and serves as the President of Mulroy Advisors, LLC. Mr. Mulroy served until September 2014 as Executive Vice President – Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Mr. Mulroy was appointed Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor in February 2014, having previously served as Chief Financial Officer, General Counsel and Corporate Secretary since January 2011. From 2003 to 2011, Mr. Mulroy was employed by the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, and represented Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch. From July 2011 to August 2014, Mr. Mulroy served as a member of the Board of Directors of Comarco, Inc., which developed and designed innovative technologies and intellectual property used in power adapters.
Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. (Economics) from the University of Chicago. Mr. Mulroy brings to our Board his experience as a strategic planner and as legal counsel and member of a senior management team of a growing biopharmaceutical company. Mr. Mulroy also brings to our Board his experience in corporate finance and investor relations.